<DOC>
	<DOC>NCT01313247</DOC>
	<brief_summary>Randomised, double-blind placebo controlled cross-over trial Main goal: Optimize the medical pain treatment for patients with advanced cancer disease Study goal: Measure paracetamol's additional analgesic effect in a situation where the patient is concomitantly treated with oral opioids eqv. morphine &gt; 100 mg/d.</brief_summary>
	<brief_title>Paracetamol for Cancer Pain</brief_title>
	<detailed_description>National multicenter study with an intention to include 50 patients. 6 days treatment, 3d in each arm. Mean pain score last 24 h: NRS =/&gt; 4 All drug treatment constant during the study period. The participants are allowed to take as much rescue opioids as necessary to have adequate relief. Paracetamol/ placebo given orally 1000 mg x 4 daily, three days in each arm, direct crossover. Daily scoring of pain relief, ESAS, overall satisfaction and rescue medication.</detailed_description>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Adults (&gt; 18 years) of both sexes Diagnosed with advanced cancer disease Ongoing medicinal pain relief treatment in stable dosing with oral opiates equivalent to &gt; 100 mg oral morphine daily NRS median pain score last 24 hrs &gt; 4 Able to take tablets (paracetamol) orally Mental or physical deficiency precluding data collection. Reduced liver function judged with bilirubin, INR and transaminases Anticoagulation with warfarin Ongoing use of NSAIDs or 5HT3 antagonists, or use of such drugs last week Ongoing palliative radiation treatment or radiation treatment during the last 4 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Paracetamol</keyword>
	<keyword>opioids</keyword>
	<keyword>cancer pain</keyword>
</DOC>